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Abstract 
The overall goal of this project was to investigate the simultaneous use of magnetic iron-oxide 
nanoparticles (MNPs) for cancer treatment using hyperthermia as well as contrast agents that will allow 
MRI visualization of the particles within the tumor. Following characterization of the particles for use as 
both a therapeutic and MRI diagnostic agent, a strategy was designed for using MNPs in localized 
hyperthermia treatment of tumors; where MRI is used to both confirm the tumor uptake of the particles 
and as a tool to monitor the temperature changes in the tumor tissue during hyperthermia treatment. 
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I. Introduction 
Magnetic Resonance Imaging (MRI) is a well-established clinical imaging modality for visualizing 
soft tissue in the body.  MRI can be used alone or in conjunction with MRI contrast agents to enhance 
MR images.  One class of MRI contrast agents is based on iron-oxide nanoparticles.  In addition to their 
MRI contrast properties, iron-oxide nanoparticles can be used as an adjunct for killing cancerous tumor 
cells using hyperthermia.  Hyperthermia is the process of heating tissue above normal physiological 
temperature.  During hyperthermia, iron-oxide particles have the property that they can absorb and 
conduct heat more easily than body fluids and tissue alone.  Iron-oxide particles can concentrate and 
conduct heat in an area that is specific to the location of the particles.  In the case of cancers, the tumor 
vasculature is generally “leaky”, allowing the particles to selectively concentrate in those regions as 
compared to healthy normal tissue.  It is also important to note that the temperature to kill cancerous 
cells is lower than that of healthy cells.  Consequently, using hyperthermia in conjunction with localized 
iron-oxide particles allows more heat to be selectively applied to the tumor; thus minimizing heat 
damage to the surrounding normal tissue.  This project focuses on the development and 
characterization of iron-oxide nanoparticles for dual-use as:  (1) a diagnostic MRI contrast agent that will 
allow MRI verification of tumor uptake of the particles; (2) a therapeutic adjunct to facilitate more 
effective localized heating of tumor tissue during hyperthermia.   
To investigate the possibilities for using iron-oxide nanoparticles as dual-use diagnostic and 
therapeutic agents, a thorough literature review was performed to understand the wide range of 
potential applications for these agents.  Following the literature review, an engineering design analysis 
was performed to determine the optimal conditions for image-guided hyperthermia using iron-oxide 
nanoparticles.  As part of this project, the MRI and hyperthermia properties of the iron-oxide 
nanoparticles were characterized.  Once this characterization was performed, the feasibility of using 
iron-oxide nanoparticles as dual-use diagnostic and therapeutic agents was evaluated.   
Goal 
The goal of this project is to characterize the MRI and hyperthermia properties of iron-oxide 
nanoparticles and then design and evaluate an optimal diagnostic/therapeutic strategy for the use of 
these agents for image-guided hyperthermia of tumors. 
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II. Literature Review 
1. Magnetic Resonance Imaging (MRI) 
i. MRI background information 
 
Magnetic Resonance Imaging (MRI) has been used as a diagnostic tool in medicine for about 
thirty years and is based on the Nuclear Magnetic Resonance (NMR) technique.  MRI uses a very strong 
magnetic field to polarize hydrogen nuclei (usually from water and fat) in the body; that is, the nuclei 
align themselves in either a “parallel” or “anti-parallel” orientation with respect to the main magnetic 
field direction.  The polarized nuclei are then excited with a radiofrequency (RF) pulse; which is applied 
at a frequency specific to the nuclei and the strength of the main magnetic field.  Immediately following 
the application of the RF pulse, the MRI signal is detected.  The frequency and phase of the signal 
contains information about the spatial location of nuclei within the body.  The MRI signal intensity is 
proportional to:  (1) the number (concentration) of nuclei at a particular location in space; (2) the rate at 
which the nuclei re-align themselves in the main magnetic field following the RF excitation pulse – which 
is characterized by the T1 relaxation time; and (3) the rate of decay of the MRI signal itself during the 
signal-measurement period – which is characterized by the T2 relaxation time.  Different tissues in a MR 
image are distinguished from one another based on differences in signal intensity that arise from 
differences in the concentration and T1 and T2 relaxation times of water protons in the respective 
tissues. 
A schematic of a human MRI magnet assembly is shown in Figure 1 .  The patient lies supine and 
is placed in the center of the magnet assembly.  The magnet itself produces the main magnetic field 
along which the hydrogen atoms align.  Within the MRI magnet assembly – also surrounding the patient 
– is radiofrequency (RF) coil which transmits RF pulses through the patient’s body in order to excite the 
nuclei.  After the RF pulse is turned off, the nuclei return to their initial equilibrium condition.  During 
this process, an electrical current – proportional to the MRI signal – is induced into the same RF coil that 
was used to excite the nuclei in the first place.  The MRI signal is digitized and – with subsequent digital 
signal processing – converted to the MR image.  Also within the magnet assembly are a set of three 
magnetic field gradient coils.  The geometry and relative orientation of these coils allow linear magnetic 
field gradients to be applied along the x, y, and z directions of a Cartesian co-ordinate frame within the 
magnet assembly.  By applying current to the magnetic-field-gradient coils, the spatial location of nuclei 
within the patient can be encoded into the frequency and phase of the measured MRI signal.  
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Depending upon which magnetic-field-gradient coils are used, “sliced” images may be obtained from 
specific parts of the body.
 
Figure 1: MRI Magnet Assembly Cutaway
1
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Figure 2: Magnetic Field Gradient Coils and Radiofrequency (“Transceiver”) Coil within MRI Magnet Assembly
1
 
 
 
Figure 3: Nomenclature for MRI Slice Orientation in the Human Brain
1
 
  
MRI is generally used for the imaging of soft tissues and internal organs. It is possible to 
differentiate the different tissues and organs on the basis of differences in their respective water 
concentrations, T1 and T2 relaxation times.  MRIs are important noninvasive diagnostic tools; before 
MRIs, doctors often had to perform surgery to discover the root of a patient’s problems.  MRIs are 
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optimal in imaging because they can take images of slices of an organ or tissue and then software can 
put those slices together to form a three dimensional image of the tissue or organ of interest.  MRI is 
also a preferred method of imaging because it uses non-ionizing electromagnetic radiation 
(radiofrequency); which means it does not break chemical bonds in the process of producing an image in 
contrast to x-ray imaging techniques which have the potential to do so.   
ii. T1 Weighted Images 
 
As mentioned in the MRI background, MRI uses a very strong magnetic field to polarize 
hydrogen nuclei (usually from water and fat) in the body.  That is, the nuclear magnetic moments of the 
hydrogen nuclei within the body will align themselves in either a “parallel” or “anti-parallel” orientation 
with respect to the direction of the main magnetic field (B0).  Statistically, about half of the nuclei align 
themselves in one of the two possible orientations. However, there is a slight bias for the “parallel” 
alignment, thus leading to a small population difference between the two orientations. The summation 
of the nuclear magnetic moments for the population difference results in a net magnetization vector 
aligned with the B0 field direction.  By convention, the B0 field direction coincides with the +z axis of a 
Cartesian coordinate reference frame.  The magnitude of the net magnetization vector is maximal at the 
Boltzmann equilibrium; i.e., the time point at which all of the nuclei have come to thermal equilibrium 
after placing the sample into the magnet.  The magnitude of the Boltzmann equilibrium magnetization is 
designated as M0.  This longitudinal or z-component of the nuclear magnetization can be measured by 
applying a radiofrequency (RF) pulse of the appropriate frequency and magnitude.  
The time decay constant at which the longitudinal or z-component of the nuclear magnetization 
returns to Boltzmann equilibrium is known as the T1 relaxation time. Various tissues throughout the 
body have different T1 relaxation times. By choosing optimal experimental parameters while conducting 
an MRI, the MR image will dramatize the effects of the T1-relaxation-time differences between varying 
tissues, appearing as contrast and is denoted as a T1 weighted image. This is a desirable effect if the T1 of 
the two adjacent tissues have differing T1 relaxation times.  As will be discussed in further sections, the 
T1 relaxation time difference between tissues can further be differentiated by making use of T1 contrast 
agents.   
Another relaxation time that may differ between tissues is the T2 relaxation time. Images can 
also be weighted with T2, as well as a third parameter, proton density. The weighting of the image is 
determined for each situation by adjusting the MRI experimental parameters. For T1 weighted images, 
long TE and TR values are desired. The various timing parameters will be evaluated later.  
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iii. T2 Weighted Images 
 
Following the application of the RF excitation pulse, a signal-intensity decay curve can be 
measured as the nuclei begin to relax back to the equilibrium state. The observed time constant 
associated with the signal-intensity decay curve is due to the loss of phase coherence among nuclei 
oriented at an angle with respect to the static magnetic field.  The decay time constant is denoted as 
T2*.  Several parameters contribute to T2*and are summarized in the following equation: 
 
1
𝑇2
∗ =
1
𝑇2(𝐼𝑛𝑡𝑟𝑖𝑛𝑠𝑖𝑐 )
+
1
𝑇2(𝐼𝑛𝑕𝑜𝑚𝑜𝑔𝑒𝑛𝑒𝑖𝑡𝑖𝑒𝑠 )
+
1
𝑇2(𝑆𝑢𝑠𝑐𝑒𝑝𝑡𝑖𝑏𝑖𝑙𝑖𝑡𝑦 )
+
1
𝑇2(𝐷𝑖𝑓𝑓𝑢𝑠𝑖𝑜𝑛 )
+ ⋯ 
Equation 1: Parameters which contribute T2* decay time constant. 
 
T2(Intrinsic) denotes the intrinsic spin-spin or transverse relaxation time of the nuclei themselves, 
T2(Inhomgeneiities) refers to contributions from inhomogeneities in the main magnetic field, T2(Susceptibility) 
susceptibility refers to contribution from local magnetic field inhomogeneities that arise within the 
tissue itself, and T2(Diffusion) refers to contributions from molecular water diffusion in the tissue.  Thus, the 
value of T2* will always be much less than or equal to the intrinsic value of T2. 
The intrinsic T2 value of Equation 1 is one the parameters used to generate contrast in MR 
images by exploiting differences in this parameter for different tissues in the image.  By using an MRI 
method based on a spin-echo RF pulse sequence, the effects of magnetic field inhomogenities and 
susceptibility effects (the second and third terms in the right-hand side of the above equation) can be 
minimized.  Furthermore, diffusion effects are usually minimal when using a spin-echo pulse sequence 
under clinical imaging conditions.  Consequently, using a spin-echo MRI pulse sequence, MR image 
contrast can be generated based on the intrinsic T2 value alone. For T2-weighted images, short TE and TR 
values are required; once again, these timing parameters will be discussed in later sections. 
2. MRI contrast agents 
In addition to the intrinsic contrast mechanisms associated with MRI (i.e., proton concentration, T1 
and T2 relaxation times), various MRI contrast agents can be used to enhance the contrast (i.e., signal 
intensity differences) between different types of tissues being imaged.  The agents are able to do this by 
varying the T1 and T2 relaxation times
1.  One class of MRI contrast agents are commonly paramagnetic 
metal ions such as gadolinium.  The problem with the use of gadolinium and other paramagnetic metal 
ions alone is that they can be highly toxic.  Consequently, these ions are often combined with organic 
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molecules to minimize their toxicity following introduction to the body.  A common use for contrast 
agents is the diagnosis of tumors. Due to the increased permeability of tumors (particularly in the brain) 
relative to the surrounding normal tissue, the contrast agent can preferentially accumulate in the tumor 
creating strong regional contrast in the MR image. 
Another class of MRI contrast agents is based on iron-oxide particles.  Feridex I.V. is a super-
paramagnetic iron oxide contrast agent available by AMAG Pharmaceuticals Inc. Feridex is stabilized 
with a dextran coating, and is administered intravenously.  Feridex I.V. is currently commercially 
available and is widely used for the detection and diagnosis of liver lesions.  According to manufacturer 
specifications, the concentration of iron in an I.V. dosage of Feridex is 0.56 mg Fe per Kg of body weight.   
GastroMARK, also by AMAG Pharmaceuticals Inc., is also used clinically as a super-paramagnetic 
iron oxide contrast agent.  However, this product is administered orally and is primarily used for imaging 
the bowel and abdominal regions.   
i. T1 and T2 Contrast Agents 
Usually, the T2 relaxation times of cancerous tissue and surrounding normal healthy tissue have 
different values. For example, normal liver tissue may have a T2 of 0.043 seconds, and a cancerous lesion 
found in the liver may have a T2 of 0.056 seconds. Furthermore, cancerous tissue usually has higher T1 
values than the surrounding normal tissue. This is due to the fact that diseased tissue usually has higher 
water content than normal tissue, mainly due to inflammatory response. The relative differences in 
water content and T1 and T2 relaxation times between diseased and normal tissue is what gives rise to 
the contrast in the MR image, and allows radiologists to diagnose tumors.  
ii. Iron-oxide as an MRI contrast agent 
Super-paramagnetic iron oxide particles can be used as negative contrast agents. Because of 
their magnetic properties, they cause both inhomogenities in the local field and in the sample itself 
(susceptibility).  The inhomogenities that the particles present lead to further decreased T2 relaxation 
times of the healthy tissue. The larger difference between the two T2 relaxation times leads to greater 
contrast between the healthy tissue and diseased tissue. 
Iron oxide nanoparticles are particularly useful as MRI contrast agents because of their strong 
magnetic properties.   The interaction between the water molecules in the vicinity of the strong local 
magnetic field of the particles results in a shortening of the T1 and T2 relaxation times of the water 
protons.  The shortening of the T2 time is due to the difference in magnetic sensitivity between the 
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particle medium and the surrounding tissue which causes “microscopic field gradients” that “lead to de-
phasing of the proton magnetic moments”2.  Iron oxide nanoparticles also have desirable 
biocompatibility and biodegradability properties; in contrast to the gadolinium MRI contrast agents 
discussed earlier, which can be toxic in the body. 
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iii. Iron Particle Concentration for MRI 
 
To function as both a diagnostic and therapeutic agent, the concentration of iron oxide particles 
must be appropriate for both applications.  When used as a diagnostic MRI contrast agent, Jain et  al.3 
have shown that concentrations between 0.5 and 50 µg Fe/mL are required to effectively decrease 
signal intensity in an MRI.  Figure 4 is from Jain et al. and shows the change in MRI signal intensity in a 
spin-echo pulse sequence as a function of the echo time (TE) for a range of concentrations of iron oxide 
particles.  As the concentration of iron increases, the rate of signal-intensity decay also increases.  Over 
the range of TE values typically used in clinical imaging (ranging from 10 – 90 msec), the figure shows 
that iron concentrations between 0.5 and 50 µg Fe/mL will provide significant signal attenuation (and 
hence MRI contrast) in tissue regions where the particles are sequestered (e.g., in tumors). 
 
Figure 4: Plot of Signal Intensity as a Function of Echo Time (TE) for a Spin-Echo MRI Pulse Sequence for Varying 
Concentrations of Iron Oxide Particles.
3
 
 
Figure 5 shows a series of MR images from solutions containing varying concentration of iron 
oxide particles.  The signal intensity decreases steadily as the concentration of magnetic nanoparticles 
increases.  For these MRI conditions, very effective contrast (i.e., the darker images) is achieved at 
concentrations between 20 and 50 µg Fe/mL.  Based on the results of these studies, this iron particle 
concentration range is recommended for the diagnostic use of these types of agents as MRI contrast 
agents. 
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Figure 5: MR Images of Solutions with Varying Iron Oxide Concentrations
3
 
3. Hyperthermia 
Normal physiological temperature of the human body is about 37.0°C.  Hyperthermia is the 
process of increasing the temperature of a particular tissue region higher than this value.  Hyperthermia 
between 42.0°C and 46.0°C has been shown to alter the function of many structural and enzymatic 
proteins within cells, which leads to necrosis.4 In addition to necrotic cell death, hyperthermia may lead 
to decreases in cell growth and differentiation, and can also induce apoptosis.4 Using various targeting 
approaches, hyperthermia has been an effective method for treating tumors.  The concept of treating 
tumors with hyperthermia is appealing because it is a physical treatment as opposed to a chemical one.  
Hyperthermia has fewer side effects than chemical treatments such as chemotherapy.  Because of fewer 
side effects and the lack of toxicity, frequent hyperthermia treatments are possible.  In chemotherapy, 
there is a limitation on the frequency and overall quantity of treatments because of the toxicity it 
imparts to the rest of the body. 
Several types of hyperthermia strategies are available for tumor treatment.  A highly 
experimental, but effective type involves magnetic embolization.  Magnetic embolization hyperthermia 
consists of injecting magnetic particles, such as iron-oxide particles, directly to the site of treatment.   
When exposed to an AC magnetic field, the particles absorb energy and increase in temperature due to 
hysteresis loss.  The rate and capacity of hysteresis loss is directly related to the specific absorption rate, 
or SAR. Under these conditions, magnetic particles act as heat inductors and increase the tissue 
temperature in the immediate vicinity of the particles. Magnetic embolization hyperthermia has been 
shown to be very effective because of its inherent ability for high selectivity.  In one study, after five 
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minutes of heating, the tumor temperature reached the high forties (in degrees Centigrade) while the 
surrounding normal parenchyma one centimeter away from the particles remained below 40°C.4   
i. Factors Affecting SAR: Particle Size & Surface Modifications 
 
For effective hyperthermia treatment, a high specific absorption rate (SAR) is essential for the 
particles.  The primary factor that affects SAR is saturation magnetization.  Dennis et. al.  for example, 
have shown that a difference in saturation magnetization of a factor of 1.5 yields a difference in SAR of a 
factor of 2.5 at 1080 Oe and 150 KHz.5  There are several parameters of the particles that may lead to 
varying saturation magnetization and in turn SAR; some being particle size and surface modification. 
 Zhao et.  al.  have shown that particles within the size range of 10 to 30 nm are effective for 
hyperthermia, and found saturation magnetization to be approximately 50.05 emu/g for the given 
particle sample.6 Gupta & Gupta also report saturation magnetization levels between 30 and 50 emu/g 
for particles that are suitable for hyperthermia treatment.7 Dennis et.  al.  found that particles with the 
size of 44±13 nm and a single dextran coating have saturation magnetization around 61.64 kAm2/g and 
an SAR of 537 W/gFe.5 Additionally, they found that particles of the same core size, but with a double 
dextran layer, have decreased saturation magnetization at 41.08 kAm2/g and SAR was found to be lower 
at 209 W/gFe.5 
Therefore, for hyperthermia treatment, a particle size between 10 and 50 nm appears to be 
optimal.  Because a high SAR is desired for this application, a single dextran layer should be used for a 
particle coating as opposed to a double layer (if dextran modifications are used).  At this time, there 
have been no measurements of SAR for oleic-acid coated particles. 
ii. Iron Particle Concentration for Hyperthermia 
 
Differences in reporting the dosage and iron particle concentration by different investigators 
make it difficult to compare the results from different studies.  Zhao et.  al.  suggest a concentration of 
10 mg per mL of tumor volume.6  Dennis et.  al.  have shown that doses between 722 and 976 mg of Fe 
are effective for hyperthermia treatment.5  Tests were run with varying dosages, times, and magnetic 
field amplitudes.  The total heat dose and heat dosage rate were calculated, and the maximum 
temperature was measured.  The results of are summarized in Table 1. 
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Table 1: Effect of Varying Experimental Conditions on Hyperthermia Treatment in an In Vivo Mouse Model (from C  L. Dennis 
et.  al.
5
). 
 
 
 
For the desired final temperature of between 42.0°C and 46.0°C, Groups 2 and 3 from Table 1 
meet these criteria. These groups showed that doses between 436 and 845 mg of Fe are most effective 
as well as exposure times between 13.67 and 19.43 minutes (Groups 3 and 2, respectively). 
iii. Alternating Magnetic Field (AMF) Delivery Device 
 
In order to induce hyperthermia using iron oxide particles, an alternating magnetic field (AMF) 
delivery device is employed to impart energy to the particles – resulting in a rise in temperature.  
Frequency, magnitude/field strength, and current of the AMF delivery device must be considered.  
Additionally, exposure time of the iron oxide particles to the field is a critical factor.  Coil geometry must 
also be considered in order to accommodate varying tumor sizes and anatomical locations. 
Based on the literature, the most effective range of frequencies for hyperthermia applications is 
between 50 and 150 KHz.  One study used 80 KHz6 and recommended AMF frequencies between 50 and 
100 KHz; another study used 150 KHz5. Magnetic field strengths between 30 and 85 kA/m have typically 
been used.5, 6 
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III. Project Strategy 
To optimize the application of iron-oxide nanoparticles for use as both a diagnostic and 
therapeutic agent, a variety of evaluations are necessary.  It is of great importance to determine the 
initial client statement to ensure all parts of the design fit the requirements.  It is also necessary to 
review and analyze all of the objectives based on the client statement as well as constraints.  Once 
considering these objectives and constraints, it is necessary to review and revise the initial client 
statement.  Finally, the actual design must be formulated and supported with a variety of analyses and 
background literature. 
 
1. Client Statement and Objectives 
i. Original Client Statement 
Characterize the properties of Fe3O4 nanoparticles synthesized by Professor Yu and evaluate 
their potential applications as diagnostic and therapeutic agents. Following characterization of the 
particles, design a strategy for using iron-oxide nanoparticles in localized hyperthermia treatment of 
cancer cells and as MRI contrast agents. 
 
ii. Design Objectives 
To ensure an optimal design, it is necessary to consider all of the objectives required for the 
design.  To ensure thoroughness, primary objectives were broken up into sub-categories in objectives 
trees.  The primary objectives considered were: effectiveness, hyperthermia treatment, minimally 
invasive, safe, and simple-user-interface. These objectives are outlined in the following figures.  
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Figure 6: Objectives Tree for Effectiveness 
 
For the design to be effective, the particles must enhance the contrast of the MRI as well as be 
delivered in a way that selectively targets the tumor.  The effectiveness in the targeting of the tumors is 
considered in terms of the method of delivery.  Intravenous (IV) injection requires the particles to have a 
long plasma half-life, so that they have the maximum opportunity to traverse the leaky vasculature that 
is characteristic of many tumors.  Alternatively, the particles can be directly injected into the tumor.  
Although invasive, this method achieves a high concentration of particles at the injection site and thus 
improves the likelihood of success for the hyperthermia application.   
Effective
Enhance the 
contrast of MRI
Target Tumors
IV
particles must 
have long 
plasma half-life
Direct Injection
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Figure 7: Objectives Tree for Minimally Invasive 
 
It is desirable to have all aspects of the design be non-invasive to minimize potential risks – such 
as infection – as well as to treat tumors that are surgically inaccessible (e.g., deep within the brain).  The 
functions that need to be performed non-invasively are: monitoring of the temperatures of the tumor 
and surrounding healthy tissue and application and monitoring of the therapy. 
Minimally Invasive
Monitor Temperature 
of tumor and 
surrounding tissue
Application of 
hyperthermia therapy
Assess hyperthermia 
therapy using 
imaging techniques
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Figure 8: Objectives Tree for Safety 
 
The objective tree for safety is of greatest importance in this design.  If a design is not safe, it 
can never be used clinically and is thus useless.  There are various categories of the design that must be 
considered in safety.  In order to minimize toxicity, the magnetic nanoparticles (MNPs) need to be at a 
concentration lower than the maximum blood plasma levels or maximum dosage.   They also must be 
bio-eliminated (cleared) from the body.  Safety issues associated with the hyperthermia device include:  
maximum temperatures, maximum magnetic field absorption, and maximum allotted exposure time.  
Lastly, it is important to ensure that the diagnostic modality does not exceed radiation safety levels. 
Safe
MNPs must not 
exceed max. blood 
plasma levels or max. 
dose
MNPs must be able to 
be filtered out of the 
body in a reasonable 
time span
Hyperthermia device 
must not exceed:
max. set temperatures
Max. set magnetic 
field absorption
allotted exposure time
Diagnostic modality 
must not exceed 
radiation safety levels
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Figure 9: Objectives Tree for User Interface 
 
To ensure effective and safe use of the product – as well as appeal to its users – the device 
should have a simple user interface.  The user interface should be designed such that the temperature 
feedback for both the tumor tissue and the surrounding healthy tissue can be easily monitored for 
safety purposes.  Another part of the interface allows control of the frequency, field strength and 
duration of the A/C magnetic field.  It is important that these controls are simple for the user to ensure 
accurate therapeutic application.  Additional controls are: on/off switch, an emergency stop, start 
treatment and a numerical display of the specific absorption rate (SAR). 
Simple User 
Interface
Temp. 
Feedback
Tumor Tissue
Surrounding 
healthy tissue
A/C Control
Settings For:
Frequency
Field Strength
Time
Display 
numerical SAR
Simple 
controls:
on/off
emergency 
stop
start 
treatment
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Figure 10: Objectives Tree for Hyperthermia 
 
The objectives tree associated with hyperthermia outlines the important features of the 
therapeutic part of the device.  There are two main branches in this objectives tree: (1) the particles 
must have a high SAR, and (2) the alternating magnetic field (AMF) delivery device must provide 
adequate energy to the magnetic nanoparticles.  To have a high SAR, the particles must:  (1) have high 
saturation magnetization, (2) be delivered with an adequate concentration or dosage, and (3) have 
effective surface modification or coating.  For the AMF delivery device to provide adequate energy to 
Hyperthermia
Particles must Have a 
High SAR
High saturation 
magnetization
Delivered with 
adequate 
concentration and 
dosage
Effective surface 
modification or 
coating
AMF delivery device 
must provide 
adequate energy to 
MNPs
Effective frequency
Effective magnitude, 
current and field 
strength
Deliverance for 
sufficient time
Proper coil geometry 
to accomodate all 
sizes and parts of 
body
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the MNPs, the frequency, field strength, and duration of the A/C magnetic field must be optimized.  The 
optimization of these parameters will also be a function of the coil size and geometry; which will be 
determined by size and location of the anatomy that will be treated. 
 
iii. Revised Client Statement: 
After considering all of the objectives and what must be accounted for, it is necessary to revise 
the original client statement; the revised client statement in the following ways: 
The characterization of particles is for both hyperthermia and use as a contrast agent for MR 
Imaging.  Also, added to the client statement is that the design must be for localized hyperthermia in 
conjunction with MRI localization of the particles and MRI temperature monitoring of the hyperthermia 
treatment. 
 
For use as an MRI contrast agent, the optimal particle size, concentration (or dose), and method 
of delivery must be determined. The use of iron-oxide particles as MRI contrast agents relies on their 
intrinsic super-paramagnetic properties.   However, the strength of this effect is a function of particle 
size and concentration, which must be evaluated in order to produce optimal results.  A frequently used 
approach for delivery of the particles is direct injection. However, this approach is more invasive than 
that of intravenous delivery, which would be the most convenient and desirable method.  The toxicity 
and cost of the treatment must also be considered in the design. Although there are normal iron 
concentrations in blood, toxicity can be an issue at high concentrations.  
The cost of the treatment relative to comparable current therapeutic options must also be 
evaluated in the design.  Finally, there are a variety of potential in surface modifications to the iron 
oxide particles themselves that may improve the bio-distribution, delivery, and image contrast. This 
process would involve determining any chemical modifications of the particle surface which in turn 
would provide improved affinity for ligands of interest (e.g., surface proteins specific to cancer cells). 
Another variable to consider in optimization of treatment is the magnitude of the AC magnetic 
field. The magnitude of the field must be controlled in order to obtain the most efficient level of 
hyperthermia while at the same time maintain a safe level of magnetic emissions.  To optimize the dual 
functionality of the iron oxide particles, there are several variables that are common to both 
applications. These variables (such as particle size, dose, and method of delivery) must be optimized to 
best satisfy the requirements for both applications.  
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Based on the revised client statement, all of the needed and desired functions are considered 
along with possible means to accomplish these functions.  The functions this design must perform along 
with their possible means are seen in the table below. 
 
Table 2: Function and Means 
Function Means 
Temperature Monitoring 
Measurement of T1 
relaxation time 
H2O Chemical 
Shift 
H2O Diffusion 
Measurements 
IR Camera 
Therapeutic Application Focused Ultrasound 
External A.C. 
Magnetic Field 
Conventional 
Hyperthermia Methods 
 
Image Guided Therapy 
Assessment 
MRI CT US PET 
Tumor Targeting I.V. Administration Direct Injection   
 
As one can see from above, all potential means of accomplishing the functions required for the 
design are listed.  In the next chapter, a design will be formulated based on the feasibility of each of 
these means. 
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2. Alternative Designs 
Every function has various means that can be used in order to achieve that function.   The main 
objectives will be:  (1) temperature monitoring of the site; (2) therapeutic application of the 
hyperthermia treatment; (3) the imaging technique used to monitor the status of treatment; and (4) the 
tumor targeting technique for the optimal delivery of the iron-oxide particles. 
i. Image Guided Therapy Assessment 
There are many well established biomedical imaging techniques that can be used to visualize 
tumors.   At around $25,000-50,0008, Ultrasound is a very inexpensive modality.   It is also very safe, and 
easy to implement.  The only safety concern is that in some instances there is undesired heating of 
tissue, although this is rare9.  Ultrasound cannot penetrate bone, so imaging of the brain is impossible.  
It cannot penetrate gas either, so imaging of the lungs is also impossible.  Thus, despite being 
inexpensive and easy to implement, ultrasound would be a poor choice for the imaging modality, 
especially if brain or lung tumors are being targeted. 
CT is still relatively inexpensive, at around $160,000 for a full body scanner.10 CT does pose a 
small safety risk, because the patient is exposed to X-ray radiation.  Studies have shown that patients 
are exposed to around 22.5 mSv per full body scan11, which is relatively low and may increase a chance 
of cancer of about 1 in 2000.  The image quality of CT is less prone to motion artifact, and thus it is very 
suitable for anatomical regions which have movement such as the abdominal region. 
MRI is an extremely expensive technique, at around $3,000,000 for a 3-Tesla full body scanner.12 
However, the technique is extremely safe since the patient is not exposed to high energy radiation.  The 
only safety risk is when the patient has incompatible medical implants that may be dislodged due to the 
powerful magnetic field.13 It is generally accepted that MRI has superior image quality in the brain than 
CT or other techniques.  Because of its superior image quality, safety, and that it can be used on virtually 
any anatomical region, MRI is often the method of choice for tumor location and monitoring. 
ii. Temperature Monitoring 
In order to adhere to the client statement, the temperature monitoring modality must be non-
invasive.  There are several known methods which can be used in order to monitor temperature non-
invasively using MRI: monitoring the T1 relaxation time, the T2 relaxation time, the diffusion coefficient 
of H2O, or the magnetization transfer rate. 
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Monitoring the T1 relaxation time is a very effective method for temperature monitoring 
because the measurement can be performed quickly, thus making it very suitable for hyperthermia 
application.  A fast T1 mapping method using TOMROP allows measurement of tissue temperature in 
around 4 minutes.14  The technique is also sufficiently sensitive in that a ~1°C (shown in liver) results in a 
~1-2% change in the measured value of the T1 relaxation time. 14 
T2 relaxation time measurements have been shown to be a very ineffective method for in vivo 
temperature monitoring applications.  Temperature measurements using this approach can only be 
made at extremely low or high temperatures, both of which are out of the physiological temperature 
range of interest for this project.  Temperature measurements in these extreme cases would also lead to 
irrecoverable tissue death.15 
Water diffusion coefficient measurements have adequate sensitivity and exhibit an ~2% change 
per °C; however, lengthy acquisition times make it unsuitable for hyperthermia applications. The 
efficacy of magnetization transfer measurements for evaluating temperature are strongly tissue 
dependent, and thus the general applicability of this approach to a wide range of tissue types is quite 
limited and not lend itself to therapeutic assessment over varying anatomical regions. 
iii. Therapeutic Application 
In order to achieve the project goals, hyperthermia must be employed as a therapeutic 
approach for treating tumors.  There are three major methods of using hyperthermia for therapy.  
Conventional hyperthermia uses heated water jackets and relies on tissue conduction of heat to treat 
the affected body part.  Concentrated ultrasound therapy uses ultrasound transmitters in order to heat 
specific tissue.  Finally, the use of an alternating current magnetic field, in conjunction with magnetic 
nanoparticles, can exploit the hysteresis properties of the nanoparticles to heat the specified location. 
A conventional hyperthermia system is displayed in Figure 11.  Conventional hyperthermia is 
very safe because it simulates fever and improves the efficiency of the immune system for temperatures 
up to 40°C.  However, once body temperature exceeds 42°C, studies have shown that NK-proliferation 
(you need to define what this is) is impaired.  Conventional hyperthermia requires extremely large 
instrumentation (on the order of size comparable to an MRI machine).  Therefore, it would be very 
difficult to use both MRI and conventional hyperthermia simultaneously.  The heating process is also 
very slow; on the order of hundreds of minutes are required to achieve the desired temperature ranges. 
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Figure 11: BSD-2000 Conventional Hyperthermia 
 
A current ultrasound device for use in hyperthermia has been developed by Labthermics 
Technologies, Inc. (LTI) and is shown in Figure 12.  Concentrated ultrasound is much more specific than 
conventional hyperthermia because it is able to target particular anatomical regions.  LTI reports that 
the Sonotherm 1000 can effectively and safely deliver energy as deep as 8 cm.  However, ultrasound has 
difficulty with focusing energy selectively within irregularly-shaped tumors. 
 
Figure 12: Sonotherm 1000 Ultrasound Hyperthermia Device 
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iv. Tumor Targeting 
There are two major modalities of pharmacological administration that are compatible with 
iron-oxide nanoparticles: direct subcutaneous injection and intravenous injection. 
I.V. administration can be performed by a vast majority of healthcare professionals, and will be 
of lower cost than a treatment requiring a physician’s administration.  Access can be gained by external 
routes, and is a low invasive modality.  Additionally, it is a well-established method for drug delivery and 
has been proven to be very safe.  Reducing the size of particles improves their stealth and maximizes the 
likelihood of reaching targeted tissues.  Particles larger than 200 nm are very efficiently cleared from the 
vasculature by phagocytotic cells of the spleen, while particles smaller than 5.5 nm are removed through 
renal clearance.16 As long as particles are between 5.5 nm and 200 nm in size, I.V.  administration may 
prove to be a very effective method by maximizing the residence time in the vasculature which in turn 
increases the likelihood of tumor uptake of the particles . 
Direct injection may require surgery and a skilled physician in order to effectively administer the 
particles.  This does not adhere to the non-invasive requirement of the client statement.  The safety of 
direct injection is also compromised if a tumor site such as the brain is being targeted.  However, direct 
injection does guarantee the highest percentage of particle delivery to a given area. 
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v. Pairwise Comparison Charts  
The following functions have potential to be fulfilled with varying means: temperature 
monitoring, therapeutic application, tumor targeting, and image guided therapy assessment.  First, the 
various attributes of each function were weighed against each other. The proceeding tables summarize 
this weighting process. When the function on the left column is more important than the function on 
the top row, a “1” is placed in the cell; otherwise a “0” is placed in the cell. A final score is computed by 
summing the row for each function. The weight is then determined by dividing the individual score for 
each function by the total score of all functions. Some of the totals of weight are 110% in order to avoid 
ease of use being negated completely. 
 
Table 3: Temperature Monitoring 
 Cost 
Compatibility 
with AMF 
Device Safety 
Easy 
To 
Use Sensitivity 
Reading 
Time Score Weight 
Cost   0 0 1 0 1 2 0.13 
Compatibility 
with AMF 
Device 1   0 1 0.5 1 3.5 0.23 
Safety 1 1   1 1 1 5 0.33 
Easy To Use 0 0 0   0 0.1 0.1 0.01 
Sensitivity 1 0.5 0 1   1 3.5 0.23 
Reading Time 0 0 0 1 0   1 0.07 
      Totals= 15.1 110% 
 
Table 4: Therapeutic Application 
 Cost 
Compatibility 
with Imaging Safety 
Easy To 
Use 
Energy 
Delivery Score Weight 
Cost   0 0 1 0 1 0.10 
Compatibility 
with Imaging 1   0.5 1 1 3.5 0.35 
Safety 1 0.5   1 0.5 3 0.30 
Easy To Use 0 0 0   0 0.1 0.01 
Energy Delivery 1 0 0.5 1   2.5 0.25 
     Totals= 10.1 100% 
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Table 5: Image Guided Therapy Assessment 
 Cost 
Interference 
to AMF 
Device 
Interference 
from AMF 
Device 
Easy 
To 
Use 
Image 
Quality Safety Score Weight 
Cost   0 0 1 1 0 2 0.13 
Interference to 
AMF Device 1   0.5 1 1 0 3.5 0.23 
Interference 
from AMF 
Device 1 0.5   1 1 0 3.5 0.23 
Easy To Use 0 0 0   0.5 0 0.5 0.03 
Image Quality 0 0 0 0.5   0 0.5 0.03 
Safety 1 1 1 1 1   5 0.33 
      Totals= 15 110% 
 
Table 6: Tumor Targeting 
 Cost Non-Invasiveness Safety 
Easy To 
Use 
Particle 
Delivery Score Weight 
Cost   0 0 1 0 1 0.10 
Non-Invasiveness 1   0 1 0 2 0.20 
Safety 1 1   1 0.5 3.5 0.35 
Easy To Use 0 0 0   0 0.1 0.01 
Particle Delivery 1 1 0.5 1   3.5 0.35 
     Totals= 10.1 110% 
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vi. Numerical Evaluation Matrices  
Once the attributes are weighted, the different means can be scored against each other. The 
means are ranked from one to the number of means for that function. For example, therapeutic 
application has three means, so for each attribute (cost, safety, etc), the means are ranked from one to 
three; where three is the best in that category and one is the worst. The weighting from the previous 
section determines how much that attribute will contribute to the final score of that mean as a total. 
Lastly, the final score will determine what means will be chosen for the design (higher score is better). 
The final decisions are selected in red. 
 
       Table 7: Temperature Monitoring 
 Sensitivity Reading Time Score 
Proton Density 5*0.23=1.15 5*0.07=0.35 1.50 
T1 Relaxation 
Time 6*0.23=1.39 6*0.07=0.42 1.81 
T2 Relaxation 
Time 1*0.23=0.23 1*0.07=0.07 0.30 
Diffusion 4*0.23=0.92 1*0.07=0.07 0.99 
Magnetization 
Transfer 1*0.23=0.23 1*0.07=0.07 0.30 
Proton 
Resonance 
Frequency (PRF) 1*0.23=0.23 1*0.07=0.07 0.30 
 
Table 8: Therapeutic Application 
 Cost 
Compatibility 
with Imaging Safety Easy To Use 
Energy 
Delivery Score 
Focused 
Ultrasound 3*0.10=0.30 2*0.35=0.70 2*0.30=0.60 1*0.01=0.01 2*0.25=0.50 2.11 
External A.C. 
Magnetic 
Field 2*0.10=0.20 3*0.35=1.05 3*0.30=0.90 1*0.01=0.01 3*0.25=0.75 2.91 
Conventional 
Hyperthermia 
Means 1*0.10=0.10 1*0.35=0.35 1*0.30=0.30 3*0.01=0.03 1*0.25=0.25 1.03 
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Table 9: Image Guided Therapy Assessment 
 Cost Interference 
to AMF 
Device 
Interference 
from AMF 
Device 
Easy To Use Image Quality Safety Score 
MRI 1*0.13=0.13 1*0.23=0.23 3*0.23=0.69 1*0.03=0.03 3*0.03=0.09 2*0.33=0.66 1.83 
CT 2*0.13=0.26 2*0.23=0.46 2*0.23=0.46 2*0.03=0.06 2*0.03=0.06 1*0.33=0.33 1.63 
US 3*0.13=0.39 3*0.23=0.69 1*0.23=0.23 3*0.03=0.09 1*0.03=0.03 1*0.33=0.33 1.76 
 
 
Table 10: Tumor Targeting 
 
 
  
 Cost 
Minimal- 
Invasiveness Safety Easy To Use 
Particle 
Delivery Score 
I.V. 
Administration 2*0.10=0.20 2*0.20=0.40 2*0.35=0.70 2*0.01=0.02 1*0.35=0.35 1.67 
Direct Injection 1*0.10=0.10 1*0.20=0.20 1*0.35=0.35 1*0.01=0.01 2*0.35=0.70 1.36 
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3. Conceptual Design 
After thorough analysis and consideration of all objectives, functions, means and constraints, 
the optimal design for iron-oxide nanoparticles as a hyperthermia agent is formulated as follows.  Iron 
oxide nanoparticles will be intravenously injected into the blood stream.  Due to leaky vasculature, the 
particles will concentrate in the tumor while any excess particles in other locations are cleared from the 
body.  An MRI can be used to confirm the localization of the particles in the tumor.  Once this 
confirmation is complete, an AMF device delivers an A/C magnetic field to the tumor, heating the 
particles.  As the particles are heated, MRI temperature monitoring is done to ensure normal 
physiological temperatures of the healthy surrounding tissue, and to monitor the temperature of the 
tumor.  As the particles are heated, the cancerous tumor cells are minimized.  MRI is used to monitor 
the ablation of the tumor along with the temperature.   After treatment is completed, the body will filter 
out the particles.  This conceptual design can be seen in the illustration below (Figure 13:  Illustration of 
conceptual design for hyperthermia treatment and particle delivery
 
Figure 13:  Illustration of conceptual design for hyperthermia treatment and particle delivery 
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IV. Experimentation 
1. Inversion Recovery Background 
Method to measure T1 
Inversion recovery (IR) is a nuclear magnetic resonance (NMR) technique used to measure the 
T1 (spin-lattice) relaxation time of nuclear spins.  In this method, the net magnetization vector, M0, is 
inverted (i.e., rotated from the +z axis to the –z axis of the Cartesian coordinate reference frame) using a 
180° RF pulse (see Fig. 1).  During the time period TI following the 180° RF pulse, the nuclei will relax 
back to their Boltzmann equilibrium alignment by dissipating energy to their surroundings (i.e., the 
“lattice”).  Before the magnetization fully returns to the Boltzmann equilibrium, however, a 90° RF pulse 
is applied in order to flip the magnetization into the transverse plane.  Once in the transverse plane, the 
magnetization vector length can be measured (because longitudinal magnetization cannot be measured 
directly).  At shorter values of TI, the magnitude of the longitudinal magnetization vector will be 
negative.  At longer values of TI, the longitudinal magnetization vector becomes positive.  The 
longitudinal magnetization recovers exponentially back to the Boltzmann equilibrium with a time 
constant that is equal to T1. 
 
 
Figure 14: Inversion Recovery RF Pulse Sequence 
 
The Bloch equation for inversion is shown below, where Mz(t) is the acquired magnetization at 
time t (or TI in Figure 14), M0 is the Boltzmann equilibrium magnetization, and T1 is the relaxation time 
of the nuclei being measured. 
𝑀𝑧 𝑡 = 𝑀0  1 − 2𝑒
−𝑡
𝑇1     
Equation 2 
 
It is clear that with sufficient data samples, 𝑀𝑧 𝑡 , at varying times, the T1 of the material can be 
calculated. As previously mentioned, the measurements of Mz are closest to –M0 at earlier acquisition 
times, and closest to M0 at the later acquisition times.  
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2. NMR T1 Relaxivity Measurements 
Inversion recovery was used to measure the T1 relaxation time for the iron-oxide particles. The 
signal intensity is measured at intervals of TI, for a total of 23 measurements for each concentration. 
The first measurement was taken at TI = 0.005s, and the last measurement was taken at TI= 8s.  Figure 
15 shows inversion recovery plots for the 14.4 nm particles as a function of concentration.  Figure 16 
shows the analogous plots for the 32.4 nm particles. 
 
Figure 15: Plot Inversion recovery data for 14.4 nm iron-oxide particles as a function of concentration. 
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Figure 16: Plot of Inversion recovery data for 32.4 nm iron particles as a function of concentration. 
 
The relaxation curves shown in the above plots were fitted to Equation 1 using MATLAB’s Curve 
Fitting Toolbox and the T1 relaxation time was calculated at each concentration.  The relaxation rates, R1 
(=1/T1), were then calculated at each concentration and these data are summarized in the following 
table. 
 
Table 11: R1 (1/sec) and T1 (sec) for 14.4nm and 32.4nm iron particles as a function of concentration 
Concentration 
(µg/mL) 
T1, 
14.4nm 
R1, 
14.4nm 
T1, 
32.4nm 
R1, 
32.4nm 
5 2.76 0.36 2.59 0.39 
10 2.27 0.44 2.53 0.40 
20 1.81 0.55 2.44 0.41 
30 1.53 0.65 2.40 0.42 
50 1.12 0.89 2.00 0.50 
 
The R1 values were then plotted as a function of concentration and linear regression was 
performed on the data to determine the slope of the best-fit straight lines.  The slope of the line is 
referred to as the relaxivity, r1, and is a measure of the efficiency with which the particles promote spin-
lattice (T1) relaxation. The squared correlation coefficient, R
2, 0.997 for the 14.4nm particles and 0.903 
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for the 32.4nm particles, demonstrated a good linear correlation of the data.  The r1 value for the 14.4 
nm particles is 11.5 x 10-3 mL(sec-1)(µg-1).  The 32.4 nm particles have an r1 value of 2.4 x 10
-3 mL(sec-
1)(µg-1). 
 
Figure 17: Plot of R1 relaxation rates for 14.4nm and 32.4nm iron particles as a function of concentration.  The slope of each 
line corresponds to the relaxivity, r1, for each particle size. 
 
3. Hahn Spin Echo Background 
Method to measure T2 
  
The Hahn spin echo (SE) method is used to measure the T2 (transverse) relaxation time of 
nuclear spins. The SE begins with a 90° radio frequency (RF) excitation pulse (see Figure 18), which 
rotates the longitudinal magnetization into the transverse plane.  The transverse magnetization then 
begins to precess about the longitudinal axis.  During this process, the precessional speed of the 
individual nuclear magnetic moments that comprise the transverse magnetization will vary slightly; 
resulting in a de-phasing (and hence attenuation) of the magnetization vector.  After a waiting period t, 
a 180° RF pulse is applied in order to reverse the positional relationship between individual nuclear 
magnetic moments in the transverse plane.  In this case, the faster precessing nuclei will now be 
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positioned behind the slower precessing nuclei (as compared to being ahead prior to the application of 
the 180° RF pulse). After a second time t has elapsed, the transverse magnetization will re-phase and is 
attenuated only by the intrinsic T2. The 180° RF pulse effectively rids the T2 measurement of any 
dependence on B0 field inhomogeneities or susceptibility effects arising from the sample.  The equation 
which describes the SE signal intensity is shown below: 
𝑀𝑧 2𝑡 = 𝑀0  𝑒
−2𝑡
𝑇2    
 
Equation 3 
 
 
Figure 18: Hahn Spin Echo RF pulse sequence 
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4. NMR T2 Relaxivity Measurements 
  
The Hahn spin echo was used to perform the T2 relaxation analysis on the iron-oxide particles as 
a function of concentration (5, 10, 20, 30, and 50µg/mL).  The SE signal intensities were acquired for 
increasing echo times (TE; where TE = 2t in Equation 3).  The T2 relaxation analysis was performed for 
both 14.4 nm and 32.4 nm particles.  The measurement results are shown in Figure 19 and Figure 20. 
 
Figure 19: Plot of spin echo signal intensity as a function of echo time (TE) for 14.4nm iron oxide particles at various 
concentrations. 
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Figure 20: Plot of spin echo signal intensity as a function of echo time (TE) for 32.4nm iron oxide particles at various 
concentrations. 
 
This relaxivity data was fitted using the following exponential formula in Equation 3, the 
corresponding fitted data is shown in Figure 19 and Figure 20 using MATLAB’s Curve Fitting Toolbox and 
the T2 relaxation time was calculated at each concentration.  The relaxation rates, R2 (=1/T2), were then 
calculated at each concentration and these data are summarized in the following table. 
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Table 12: R2 (1/sec) and T2 (sec) for 14.4nm and 32.4nm iron particles as a function of concentration. 
Concentration 
(µg/mL) 
T2, 
14.4nm 
R2, 
14.4nm 
T2, 
32.4nm 
R2, 
32.4nm 
5 0.0820 12.19 0.1353 7.39 
10 0.0424 23.57 0.0588 17.01 
20 0.0227 44.09 0.0377 26.50 
30 0.0137 72.94 0.0276 36.21 
50 0.0091 110.27 0.0155 64.52 
 
 
Figure 21: r2 values for 14.4nm and 32.4nm 
The R2 values were then plotted as a function of concentration and linear regression was 
performed on the data to determine the slope of the best-fit straight lines.  The slope of the line is 
referred to as the relaxivity, r2, and is a measure of the efficiency with which the particles promote spin-
spin (T2) relaxation. The squared correlation coefficient, R
2, 0.995 for the 14.4nm particles and 0.991 for 
the 32.4nm particles, demonstrated a good linear correlation of the data.  The r1 value for the 14.4 nm 
particles is 2.21 mL(sec-1)(µg-1). The 32.4 nm particles have an r1 value of 1.22 mL(sec
-1)(µg-1). 
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5. Summarized Relaxivity Results 
 
Table 13: T1 and T2 relaxivities of the 14.4nm and 32.4nm Iron-oxide particles 
Sample 
T1 Relaxivity (r1) 
            mL(sec-1)(µg-1) 
Squared 
Correlation 
Coefficient (R2) 
T2 Relaxivity (r2) 
             mL(sec-1)(µg-1) 
Squared 
Correlation 
Coefficient (R2) 
14.4nm Iron 
Particle 
11.5 x 10-3 0.9978 2.21 0.995 
32.4nm Iron 
Particle 
2.4 x 10-3 0.9036 1.22 0.9916 
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6. Experimental Analysis  
Iron-oxide nanoparticles are excellent candidates for brain tumor contrast enhancement. 
Normal brain tissue is protected by the blood-brain barrier; however, tumors possess leaky vasculature 
and have often compromised the blood-brain barrier. The lack of a blood-brain barrier in the vicinity of 
brain tumors gives rise to an excellent opportunity for the tumor to uptake particles for therapeutic or 
diagnostic applications. In order to effectively use the iron-oxide nanoparticles as an MRI contrast agent, 
they must be characterized using nuclear magnetic resonance.  
 Brain tissue is divided into two major classifications: white and gray matter. The central portion 
of the brain consists of white matter which contains the interconnections of the brain structures. The 
outer coating of the brain consists of gray matter. A previous study showed that the average T1 value for 
gray and white matter was 1331 and 832 msec,  respectively, at 3.0 Tesla.17  Average T2 values for gray 
and whiter matter are 80 and 110 msec, respectively, at 3.0 Tesla.17   Higher relaxation times are present 
in gray matter due to the higher water content. Even higher relaxation times are expected in tumors. 
Based on 1.5 and 8.5 Tesla measurements, the relaxation times for a tumor can be estimated to be 
typically around 1500 msec and 135 msec for T1 and T2, respectively. While it has been found that the 
water content of the brain overall is around 77%, studies have shown that the white matter is 
approximately 70% water18, and the gray matter is approximately 80% water19. The water content of 
gray matter is very close to that of the water content in tumor tissue. The water content in tumor tissue 
is usually around 83%20, however, it can vary greatly. The water content of a tumor is the highest for any 
tissue of interest. For this reason, for the analysis, proton density will be normalized to that for the 
tumor. The proton density for white and gray matter can be relatively adjusted and are shown in the 
following table, along with other parameters of interest. 
 
Table 14: Average relaxation times, water content, and relative proton density for white and gray matter, and a typical 
tumor 
 T1 (msec) T2 (msec) Water Content Proton Density 
White Matter 832 80 70% 0.84 
Gray Matter 1331 110 80% 0.96 
Tumor 1500 (Estimate) 135 (Estimate) 83% 1.0 
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 As shown in the previous section, the following equations can be used to characterize the R1 and 
R2 (relaxation rates) for the different particle sizes at 3.0 Tesla: 
𝑅1 14.4 𝑛𝑚 = 0.011 ∗ 𝐶𝑜𝑛𝑐 + 0.315 
𝑅1 32.4 𝑛𝑚 = 0.002 ∗ 𝐶𝑜𝑛𝑐 + 0.365 
𝑅2 14.4 𝑛𝑚 = 2.210 ∗ 𝐶𝑜𝑛𝑐 + 1.765 
𝑅2 32.4 𝑛𝑚 = 1.220 ∗ 𝐶𝑜𝑛𝑐 + 2.263 
Equation 4: Relaxation rates at 3T for iron-oxide particles in solution 
 
However, these NMR results were observed while the particles were in solution. Since the 
particles will be used for contrast enhancement in tumors, the y-intercept of the previous equations can 
be replaced with the R1 and R2 values for a typical tumor. Previously, it has been estimated that tumor T1 
and T2 are approximately 1500 and 135 msec, respectively. R1, 2 values are simply the inverse of T1, 2 
values, so the typical R1 and R2 of a tumor are around 0.67 and 7.4 msec
-1, respectively. The collective 
equations for the relaxation rates for a tumor with the particles infused are shown in the following 
equations: 
𝑅1 14.4 𝑛𝑚 = 0.011 ∗ 𝐶𝑜𝑛𝑐 + 0.67 
𝑅1 32.4 𝑛𝑚 = 0.002 ∗ 𝐶𝑜𝑛𝑐 + 0.67 
𝑅2 14.4 𝑛𝑚 = 2.210 ∗ 𝐶𝑜𝑛𝑐 + 7.4 
𝑅2 32.4 𝑛𝑚 = 1.220 ∗ 𝐶𝑜𝑛𝑐 + 7.4 
Equation 5: Relaxation rates at 3T for tumors with embedded particles 
 
 …where Conc is the concentration of iron in µg/mL and the R values will be given in msec-1. 
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The results of the previous equations are shown in the following plots creating in MATLAB: 
 
Figure 22: Water relaxation rates for iron-oxide particles in solution and in tumor as a function of concentration: R1 of 
14.4nm (top left), R1 of 32.4nm (top right), R2 of 14.4nm (bottom left), and R2 of 32.4nm (bottom right). 
Using Equation 5 or Figure 22, the relaxation rates can be determined, either mathematically or 
graphically, for the tumor with embedded particles for any concentration of iron. The relaxation rates of 
the tumor with embedded particles can then be used in order to determine the effects of concentration 
on signal intensity. First, T1 relaxation analysis will be performed for effects of signal intensity on T1-
weighted image contrast.  
The average T1 relaxation times were used in order to construct T1 relaxation curves for normal 
white and gray matter. A T1 relaxation curve for a typical tumor was also plotted, based on the 
estimated relaxation time. Lastly, a series of curves were plotted which use the data from the relaxation 
rate equations for tumors with varying concentrations of particles. The relaxation curves were modeled 
using the following equation: 
𝑀𝑧(𝑇𝑅) = 𝑀0(1 − 𝑒
−𝑇𝑅
𝑇1 ) 
Equation 6  
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Figure 23: T1 relaxation analysis for normal white and gray matter, a typical brain tumor, and brain tumor with 14.4nm 
particles of varying concentrations. 
 In Figure 23, normal white matter is shown relaxing to a normalized Boltzmann equilibrium 
value of around 0.84M0; due to its relative low water content compared to gray matter and brain 
tumors as shown in Table 14. Gray matter relaxes to a Boltzmann equilibrium signal intensity of around 
0.96M0 and the brain tumor relaxes to the normalized value of M0. For a T1-weighted image, short TE 
and short TR values are typically used. If a typical TR value is chosen, for example 500 msec, the signal 
intensities between the different tissue types can be measured at that time. Shown in Figure 23 are the 
T1 curves of the tumor with particles at varying concentrations. The particles used in the above plot are 
14.4nm due to the relaxation benefits that they provide as determined and shown in the linear 
relaxation rate plots. In order to give rise to signal intensity differences (and thus give rise to contrast), 
an R1 relaxation rate of around 1.2 sec
-1 is necessary, which particles at around 47 µg/mL provide when 
embedded in a tumor. 47 µg/mL is the lowest usable concentration of particles to provide contrast. Also 
shown in the plot above are the relaxation curves for tumors with 55 µg/mL, 64 µg/mL and 72 µg/mL. 
 Using a percent difference equation, the signal intensity difference between normal tissue and 
tumors with particles can be calculated. For example: 
% 𝐷𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 =  
𝑆𝐼𝑇𝑃 − 𝑆𝐼𝑁
𝑆𝐼𝑁
∗ 100 
51 
 
Equation 7: Percentage of difference calculation for signal intensities 
where SITP is the signal intensity of the tumor with particles, and SIN  is the signal intensity of the 
normal surrounding tissue. This example can be applied for a tumor with particles of concentration of 72 
µg/mL and surrounding white matter at a TR of 500 msec: 
% 𝐷𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 =  
0.53 − 0.38
0.38
∗ 100 = 39% 
Equation 8: Percentage of signal intensity difference between normal white matter and a tumor with a concentration of 
14.4nm particles of 72 µg/mL 
 When using iron-oxide particles of 14.4nm with a concentration of 72 µg/mL embedded in a 
tumor, a signal intensity difference of 39% can be observed with normal white matter if a TR value of 
500 msec is used. The signal intensity difference between the tumor with particles and normal gray 
matter will be even greater than 39%. One can select either greater or lower concentrations of particles, 
depending on the desired contrast and the surrounding normal tissue (if the surrounding tissue is 
primarily gray matter or white matter). If concentrations as low as 47 µg/mL are used, the following 
signal intensity can be observed: 
% 𝐷𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 =  
0.45 − 0.38
0.38
∗ 100 = 18% 
Equation 9: Percentage of signal intensity difference between normal white matter and a tumor with a concentration of 
14.4nm particles of 47 µg/mL  
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Even at a concentration of 72 µg/mL , 32.4nm do not provide a high enough relaxation rate in 
order to keep the signal above the normal white and gray matter. It is expected that there would be no 
contrast between normal brain matter and a tumor with particles of 32.4nm, unless extremely, 
unfeasibly high concentrations are used. The following image display the T1 relaxation analysis for 
32.4nm particles embedded in the tumor at the same concentrations used in the previous analysis of 
14.4nm. 
 
Figure 24: T1 relaxation analysis for normal white and gray matter, a typical brain tumor, and brain tumor with 32.4nm 
particles of varying concentrations. 
 
 The plot above shows that a brain tumor with embedded 32.4nm particles at concentrations 
between 47 and 72 µg/mL does not provide any contrast enhancement. In fact, most of the signal of the 
tumor with embedded particles lies in the region of the normal white and gray matter. From an imaging 
perspective, it would be impossible to differentiate between the tumor and normal tissue. Extremely 
high concentrations around 300 µg/mL could be used in order to achieve similar contrast enhancement 
to which 14.4nm particles provide. However, the T2 signal would be completely attenuated at low TE 
values, and thus there is very little usable application of 32.4nm particles.  
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The iron-oxide nanoparticles can also be used as T2 contrast agents. In fact, super-paramagnetic 
iron-oxide particles have been known for their substantial impact on T2-weighted images. T2 relaxation 
curves were plotted for both normal white and gray matter, as well as a typical tumor. Additionally, the 
curves for tumors with particles at different concentrations and particle sizes were plotted as shown in 
Figure 25. 
 
Figure 25: T2 relaxation analysis (signal intensity as a function of the echo time TE) for normal white and gray matter, a 
typical brain tumor, and tumor with particles of varying concentrations and sizes. 
 The equation used for T2 relaxation analysis is the following: 
𝑀𝑥𝑦 𝑇𝐸 = 𝑀0 ∗ 𝑒
−𝑇𝐸
𝑇2  
Equation 10  
 For T2-weighted images, long TE and long TR times are typically used. However, when using T2 
relaxation agents such as iron-particles, shorter TE values are needed in order to maintain a good signal-
to-noise ratio (SNR). Under normal operating conditions, on clinical MRI instruments, about the shortest 
TE value that is possible with currently technology is around 8 msec. Iron particles have the capability of 
attenuating the signal substantially, however, in order to maintain good SNR, it is desired to obtain MRI 
data where the signal intensity of the tumor with particles is above 25% of M0. Equation 10 can be used 
to calculate the required T2 relaxation time in order to meet the parameters of 0.25M0 with a TE of 8 
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msec. With these parameters, a T2 relaxation time of about 0.006 seconds is required. Figure 22 can 
then be referenced in order to determine the desired particle concentration of 14.4nm particles for this 
T2 value or R2 value of 167 msec
-1(1/0.006=167). One can see that a concentration of 14.4nm particles 
around 72 µg/mL will provide a relaxation rate of around 167 msec-1. As a comparison, normal white 
matter has a signal intensity of around 75% of M0 at TE of 8 msec. Using Equation 7, the percentage of 
difference of contrast comes out to be 74%, showing that the tumor with particles comes out to be 74% 
darker than the normal white matter when using a concentration of 72 µg/mL of 14.4nm. Therefore, 
using particles at this concentration makes an excellent T2 contrast agent.  
% 𝐷𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 =   
0.19 − 0.74
0.74
 ∗ 100 = 74% 
Equation 11: Percentage of signal intensity difference between normal white matter and a tumor with a concentration of 
14.4nm particles of 72 µg/mL 
Additionally, if 32.4nm particles are used at 47 µg/mL, the signal intensity difference will be around 30%, 
which is still significant contrast. This calculation is shown below. 
% 𝐷𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 =   
0.52 − 0.74
0.74
 ∗ 100 = 30% 
Equation 12: Percentage of signal intensity difference between normal white matter and a tumor with a concentration of 
32.4nm particles of 47 µg/mL 
 
 All of the plots in this previous section were created with MATLAB, the code is available in Appendix B.  
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V. Finalized Design and Conclusion 
1. Discussion 
i. Health and Safety 
Iron is a substance found normally in the bloodstream, and the human body has little difficulty 
clearing excess amounts. A study in rats21 has shown that after one hour of intravenous administration, 
about 82% of the dose was found in the liver, and 6% was found in the spleen. Peak concentrations of 
iron were found in the liver at 2 hours, and peak concentrations of iron were found in the spleen at 4 
hours. This suggests that iron is shifted from the liver to spleen over time. In this study, all of the iron 
was cleared from the liver within 6 days, and the remaining iron was cleared from the spleen within 8 
days from the time of administration (an additional 2 days after fully cleared by the liver). In the 
conceptual design, MR imaging will be used to confirm the localization of the particles within the tumor. 
Application of the AMF will not commence until it is confirmed that all particles have either been taken 
up by the tumor, or cleared by the blood’s filtration organs. Undesirable heating of particles in other 
locations of the body will be avoided by having a waiting period between the intravenous injection and 
the application of an AMF. It is important to note that the concentration of iron-oxide particles in the 
previously discussed study was 30 mg of iron per Kg of body weight (the iron in this case was being used 
to treat anemia). With much smaller concentrations, the waiting time between administration and AMF 
application is expected to be much shorter. 
Another subject of health concern is the safety of the exposure to an alternating current 
magnetic field. A study22 showed that if the product of the frequency and amplitude of the magnetic 
field remains under 4.85x108 A/ms, undesirable neural stimulation or heating can be avoided.  It may 
also prove to be desirable, in future modifications, for the magnetic field to be concentrated locally over 
a particular body part by making use of a surface coil. This would minimize systemic exposure and 
further minimize any safety concerns. 
Lastly, there may be health concerns with the imaging and temperature monitoring methods. 
Imaging methods such as computed tomography, positron emission tomography, and ultrasound expose 
the patient to forms of radiation. However, MRI uses magnet fields for imaging and thus do not pose any 
health concerns. There only lies risk with MRI if the patient has magnetic implants, which may be 
dislodged during imaging. 
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ii. Manufacturability 
In the design process, it is important to consider manufacturability of the product.  To be able to 
manufacture this design, it is important to make sure that there are no metallic materials used in the 
MRI and AMF device.  It is also important to avoid any interference in the AC current.  Lastly, one must 
consider the process of manufacturing the MRI/AMF device along with the iron oxide nanoparticles to 
minimize cost and time. 
 
iii. Sustainability 
This device should allow for sustainability.  The device will be used for a very long time, and if 
possible, the material used in all parts of the design will be recyclable.  The design of the device will also 
allow for easy maintenance and repair to allow for longer use. 
 
iv. Environmental Impact 
The only potential environmental impact involved in this design is the potential of using 
materials that cannot be recycled after it is no longer in use. 
 
v. Societal Influence 
The primary societal influence that may arise from this design is a decrease in fatalities 
associated with cancer.  In 2008, over 560,000 people died of cancer in the United States alone23 If this 
device can kill cancerous tumor cells without killing healthy cells, there is great potential in successful 
ablation of tumors and minimal systemic side effects, thus resulting in a decrease in fatalities from 
cancer. 
vi. Ethical Concerns 
There are no particular ethical concerns associated with this design.  The only potential concern 
is for those who do not believe in the introduction of foreign materials into one’s body.  The 
introduction of iron oxide nanoparticles into the blood stream may cause concern with certain 
individuals. 
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vii. Political Influence 
A potential political influence of the design is if it is very successful, there will be a great demand 
for it.  Considering that it will cost a lot of money to manufacture and run this device, there may be a 
demand for government funding for those who cannot afford it. 
viii. Economics  
This design can contribute to every day economics in that its production will give jobs to 
chemists to produce the particles and electrical and biomedical engineers to produce the MRI and AMF 
portions of the design as well as technicians to run and maintain the device.  This device will be quite 
costly, however if it successfully and efficiently treats cancer, it will be greatly needed.  This may result 
in a need for government funds to make this treatment available to those in great need, otherwise; only 
people with very high incomes or good insurance can receive the treatment. 
2. Conclusion 
Throughout the experimental results, the optimum concentrations for MRI contrast 
enhancement were found. When used as a T1 contrast agent, the signal intensity difference between 
tumor tissue with embedded particles and normal white matter is expected to be between 18% and 39% 
for 14.4nm particles between 47 µg/mL and 72 µg/mL, respectively. When used as a T2 contrast agent, 
the signal intensity difference between tumor tissue with embedded particles and normal white matter 
is expected to be between 30% and 75% for 32.4nm particles at 47 µg/mL and 14.4nm particles at 72 
µg/mL. For hyperthermia application, the results of the literature search found the optimal AMF 
parameters to be a frequency between 80 and 150 KHz, with amplitude between 30 and 86 kA/m. 
However, these parameters are for the use of concentrations much greater than the range of 47-72 
µg/mL; on the magnitude of 3-10 mg/mL. In order to optimize heating for much smaller concentrations 
of iron, it may be necessary to use much higher frequencies and amplitudes. Higher frequencies will 
allow more efficient coupling between the particles and the AMF device itself. Higher amplitudes will 
allow for greater energy delivery and increase temperature. Another factor affecting final temperature 
that can be achieved is exposure time to the AMF. In the literature, it was found that the parameters 
discussed earlier were used for times between 5 and 30 minutes. With higher concentrations, the 
temperature increase over time is more rapid. With smaller concentrations, the temperature increase 
over time is more gradual. Therefore, it is our expectations that with greater exposure time, the same 
temperatures can be obtained. 
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 The AMF parameters can further be optimized for the specific particle size and coating in the 
application. By adjusting the size of the particles, different concentrations of iron can be obtained with 
different densities of iron particles.  Also, there is a correlation between the particle size and the 
appropriate frequency that must be used. Evidence suggests that with small particle sizes, a greater AMF 
frequency is required.  
The most effective method for temperature monitoring using MRI was found to be T1 shift 
monitoring, due to its moderate sensitivity coupled with fast acquisition time. In conclusion, MNPs have 
properties that can be used to heat cancerous tumor cells while simultaneously acting as an MRI 
contrast agent for the monitoring of particle uptake and tumor ablation. Hyperthermia treatment can 
occur while the remainder of the body, even surrounding tissue, remains at physiological temperature. 
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Appendix A: 
Relaxivity Data  
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Appendix B: MATLAB Code 
Effects of Iron Particles on Tumors 
%% EFFECTS OF IRON PARTICLES ON TUMORS 
%T1 of Tumor in Seconds 
T1tumor=1.500; 
%T2 of Tumor in Seconds 
T2tumor=0.135; 
  
R1tumor=1/T1tumor; 
R2tumor=1/T2tumor; 
  
% Concentrations used in ug/mL 
Conc=[0 5 10 20 30 50 70 90]; 
  
%R1 for 14.4nm 
subplot(2,2,1) 
grid on 
hold on 
R1initial1=0.0115*Conc+0.3156; %Eq. taken from fitted data, particles alone 
plot(Conc,R1initial1,'r') 
R1final1=0.0115*Conc+R1tumor; %Eq. for tumor with particles 
plot(Conc,R1final1,'b'); 
xlabel('Concentration (ug/mL)') 
ylabel('R1 (1/sec)') 
title('R1 Values for Tumor With 14.4nm Particles') 
legend('Iron-oxide Particles in Solution','Iron-oxide Particles in Tumor', 
'Location','SouthEast') 
  
%R1 for 32.4nm 
hold off 
subplot(2,2,2) 
grid on 
hold on 
R1initial2=0.0024*Conc+0.3655; 
plot(Conc,R1initial2,'r'); 
R1final2=0.0024*Conc+R1tumor; 
plot(Conc,R1final2,'b'); 
xlabel('Concentration (ug/mL)') 
ylabel('R1 (1/sec)') 
title('R1 Values for Tumor With 32.4nm Particles') 
legend('Iron-oxide Particles in Solution','Iron-oxide Particles in Tumor', 
'Location','SouthEast') 
  
%R2 for 14.4nm 
hold off 
subplot(2,2,3) 
grid on 
hold on 
R2initial1=2.2107*Conc+1.765; 
plot(Conc,R2initial1,'r'); 
R2final1=2.2107*Conc+R2tumor; 
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plot(Conc,R2final1,'b'); 
xlabel('Concentration (ug/mL)') 
ylabel('R2 (1/sec)') 
title('R2 Values for Tumor With 14.4nm Particles') 
legend('Iron-oxide Particles in Solution','Iron-oxide Particles in Tumor', 
'Location','SouthEast') 
  
%R2 for 32.4nm 
hold off 
subplot(2,2,4) 
grid on 
hold on 
R2initial2=1.2201*Conc+2.2635; 
plot(Conc,R2initial2,'r'); 
R2final2=1.2201*Conc+R2tumor; 
plot(Conc,R2final2,'b'); 
xlabel('Concentration (ug/mL)') 
ylabel('R2 (1/sec)') 
title('R2 Values for Tumor With 32.4nm Particles') 
legend('Iron-oxide Particles in Solution','Iron-oxide Particles in Tumor', 
'Location','SouthEast') 
 
T1 Relaxation Curves for Normal White Matter and Brain w/ Particles at 3.0T 
 
Hold on 
%% T1 Relaxation Curves for Normal White Matter and Brain w/ Particles at 
3.0T 
% R1 of Tumor with 14.4nm Particles 
R1p47=1.2; 
R1p55=1.3; 
R1p64=1.4; 
R1p72=2.5; 
T1p47=1/R1p47; 
T1p55=1/R1p55; 
T1p64=1/R1p64; 
T1p72=1/R1p72; 
  
% 3.0 Tesla Magnet Normalized from 0 to 1 signal intensity 
M0=1; 
  
% "a" Determined from Modeled Data 
a=1; 
  
%Time vector 
TR=0:0.05:6; 
  
% Normal White Matter (T1=832msec) 
Mz1=(0.84*M0)*(1-a*exp(-TR/0.832)); 
plot(TR,Mz1,'ro-') 
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% Normal Gray Matter (T1=1331msec) 
Mz1=(0.96*M0)*(1-a*exp(-TR/1.331)); 
plot(TR,Mz1,'mo-') 
  
% Brain Tumor (T1=1500msecESTIMATE) 
Mz2=M0*(1-a*exp(-TR/1.500)); 
plot(TR,Mz2,'go-') 
  
% Brain Tumor w/ Particles @ 47ug/mL 
Mz3=M0*(1-a*exp(-TR/T1p47)); 
plot(TR,Mz3,'b') 
  
% Brain Tumor w/ Particles @ 55ug/mL 
Mz3=M0*(1-a*exp(-TR/T1p55)); 
plot(TR,Mz3,'c') 
  
% Brain Tumor w/ Particles @ 64ug/mL 
Mz3=M0*(1-a*exp(-TR/T1p64)); 
plot(TR,Mz3,'k') 
  
% Brain Tumor w/ Particles @ 72ug/mL 
Mz3=M0*(1-a*exp(-TR/T1p72)); 
plot(TR,Mz3,'g') 
  
  
xlabel('TR (sec)') 
ylabel('Signal Intensity from 0 to M0') 
title('T1 Relaxation Analysis') 
legend('Normal White Matter','Normal Gray Matter','Brain Tumor','Brain Tumor 
w/ 47ug/mL Particles','Brain Tumor w/ 55ug/mL Particles','Brain Tumor w/ 
64ug/mL Particles','Brain Tumor w/ 72ug/mL Particles','Location','Best') 
  
  
  
%% T2 Relaxation Curves for Normal White Matter and Brain w/ Particles at 
3.0T 
  
%R2 of Tumor with 14.4nm Particles 
R2p47=111; 
R2p55=129; 
R2p64=149; 
R2p72=167; 
T2p47=1/R2p47; 
T2p55=1/R2p55; 
T2p64=1/R2p64; 
T2p72=1/R2p72; 
  
grid on 
hold off 
figure(2) 
grid on 
hold on 
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% Time vector 
TE=0:0.005:.1; 
  
% Normal White Matter(T2=80msec) 
Mz1b=0.84*M0*exp(-TE/0.080); 
plot(TE,Mz1b,'ro-') 
  
% Normal Gray Matter(T2=110msec) 
Mz1b=0.96*M0*exp(-TE/0.110); 
plot(TE,Mz1b,'mo-') 
  
% Brain Tumor (T2=135msecESTIMATE) 
Mz2b=M0*exp(-TE/0.135); 
plot(TE,Mz2b,'go-') 
  
% Brain Tumor w/ 47ug/mL 14nm Particles 
Mz3b=M0*exp(-TE/T2p47); 
plot(TE,Mz3b,'b') 
  
% Brain Tumor w/ 55ug/mL 14nm Particles 
Mz3b=M0*exp(-TE/T2p55); 
plot(TE,Mz3b,'c') 
  
% Brain Tumor w/ 64ug/mL 14nm Particles 
Mz3b=M0*exp(-TE/T2p64); 
plot(TE,Mz3b,'k') 
  
% Brain Tumor w/ 72ug/mL 14nm Particles 
Mz3b=M0*exp(-TE/T2p72); 
plot(TE,Mz3b,'g') 
  
  
% R2 of Tumor with 32.4nm Particles 
R2p47b=65; 
R2p55b=75; 
R2p64b=86; 
R2p72b=95; 
T2p47b=1/R2p47b; 
T2p55b=1/R2p55b; 
T2p64b=1/R2p64b; 
T2p72b=1/R2p72b; 
  
% Brain Tumor w/ 47ug/mL 32nm Particles 
Mz3b=M0*exp(-TE/T2p47b); 
plot(TE,Mz3b,'bd-') 
  
% Brain Tumor w/ 55ug/mL 32nm Particles 
Mz3b=M0*exp(-TE/T2p55b); 
plot(TE,Mz3b,'cd-') 
  
% Brain Tumor w/ 64ug/mL 32nm Particles 
Mz3b=M0*exp(-TE/T2p64b); 
plot(TE,Mz3b,'kd-') 
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% Brain Tumor w/ 72ug/mL 32nm Particles 
Mz3b=M0*exp(-TE/T2p72b); 
plot(TE,Mz3b,'gd-') 
  
xlabel('TE (sec)') 
ylabel('Signal Intensity from 0 to M0') 
title('T2 Relaxation Analysis') 
legend('Normal White Matter','Normal Gray Matter','Brain Tumor','Brain Tumor 
w/ 47ug/mL 14nm Particles','Brain Tumor w/ 55ug/mL 14nm Particles','Brain 
Tumor w/ 64ug/mL 14nm Particles','Brain Tumor w/ 72ug/mL 14nm 
Particles','Brain Tumor w/ 47ug/mL 32nm Particles','Brain Tumor w/ 55ug/mL 
32nm Particles','Brain Tumor w/ 64ug/mL 32nm Particles','Brain Tumor w/ 
72ug/mL 32nm Particles','Location','Best') 
 
